Natural history of surgically treated high-risk prostate cancer

被引:76
|
作者
Briganti, Alberto [1 ]
Karnes, Robert Jeffrey [2 ,3 ]
Gandaglia, Giorgio [1 ]
Spahn, Martin [4 ]
Gontero, Paolo [5 ]
Tosco, Lorenzo [6 ]
Kneitz, Burkhard [7 ]
Chun, Felix K. H. [8 ]
Zaffuto, Emanuele [1 ]
Sun, Maxine [9 ]
Graefen, Markus [10 ]
Marchioro, Giansilvio [11 ]
Frohneberg, Detlef [12 ]
Giona, Simone [5 ]
Karakiewicz, Pierre I. [9 ]
Van Poppel, Hein [6 ]
Montorsi, Francesco [1 ]
Joniau, Steven [6 ]
机构
[1] IRCCS Osped San Raffaele, Unit Urol, Div Oncol, URI, Milan, Italy
[2] Mayo Clin & Mayo Grad Sch Med, Dept Urol, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Univ Bern, Dept Urol, Bern, Switzerland
[5] Univ Turin, Dept Urol, Turin, Italy
[6] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[7] Univ Hosp Wurzburg, Dept Urol & Pediat Urol, Wurzburg, Germany
[8] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[9] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[10] Prostate Canc Ctr Hamburg Eppendorf, Martiniclin, Hamburg, Germany
[11] Univ Piemonte Orientale, Dept Urol, Novara, Italy
[12] Community Hosp Karlsruhe, Dept Urol, Karlsruhe, Germany
关键词
Prostate cancer; Radical prostatectomy; Biochemical recurrence; Cancer-specific mortality; Time to biochemical recurrence; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; ANTIGEN RECURRENCE; RADIATION-THERAPY; COMPETING-RISKS; IMPACT; MORTALITY; SURVIVAL; PROGRESSION; MEN;
D O I
10.1016/j.urolonc.2014.11.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: No data exist on the patterns of biochemical recurrence (BCR) and their effect on survival in patients with high-risk prostate cancer (PCa) treated with surgery. The aim of our investigation was to evaluate the natural history of PCa in patients treated with radical prostatectomy (RP) alone. Materials and methods: Overall, 2,065 patients with high-risk PCa treated with RP at 7 tertiary referral centers between 1991 and 2011 were identified. First, we calculated the probability of experiencing BCR after surgery. Particularly, we relied on conditional survival estimates for BCR after RP. Competing-risks regression analyses were then used to evaluate the effect of time to BCR on the risk of cancer-specific mortality (CSM). Results: Median follow-up was 70 months. Overall, the 5-year BCR-free survival rate was 55.2%. Given the BCR-free survivorship at 1, 2, 3, 4, and 5 years, the BCR-free survival rates improved by +7.6%, +4.1%, +4.8%, +3.2%, and +3.7%, respectively. Overall, the 10-year CSM rate was 14.8%. When patients were stratified according to time to BCR, patients experiencing BCR within 36 months from surgery had higher 10-year CSM rates compared with those experiencing late BCR (19.1% vs. 4.4%; P < 0.001). At multivariate analyses, time to BCR represented an independent predictor of CSM (P < 0.001). Conclusions: Increasing time from surgery is associated with a reduction of the risk or subsequent BCR. Additionally, time to BCR represents a predictor of CSM in these patients. These results might help provide clinicians with better follow-up strategies and more aggressive treatments for early BCR. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:163.e7 / 163.e13
页数:7
相关论文
共 50 条
  • [1] The role of radical prostatectomy as an initial approach for the treatment of high-risk prostate cancer
    Jaunarena, J. H.
    Villamil, W.
    Martinez, P. F.
    Gueglio, G.
    Giudice, C. R.
    ACTAS UROLOGICAS ESPANOLAS, 2016, 40 (06): : 353 - 360
  • [2] Oncological results in high grade prostate cancer treated surgically
    Aguilera, Alfredo
    Maria Alonso-Dorrego, Jose
    Banuelos, Beatriz
    Cisneros, Jesus
    Gonzalez, Pilar
    Diez, Jesus
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (04): : 162 - 171
  • [3] The epidemiology of high-risk prostate cancer
    Punnen, Sanoj
    Cooperberg, Matthew R.
    CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 331 - 336
  • [4] Surgery for high-risk prostate cancer and metastatic prostate cancer
    Safir, Ilan J.
    Lian, Fei
    Alemozaffar, Mehrdad
    Master, Viraj A.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 33 - 40
  • [5] Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy
    Boehle, Andreas
    Katic, Katharina
    Koenig, Inke R.
    Robrahn-Nitschke, Irina
    Brandenburg, Bernd
    BRACHYTHERAPY, 2020, 19 (01) : 24 - 32
  • [6] Prostate-specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high-risk and very high-risk prostate cancer
    Yang, Cheng-Kuang
    Yang, Chi-Rei
    Ou, Yen-Chuan
    Cheng, Chen-Li
    Ho, Hao-Chung
    Chiu, Kun-Yuan
    Wang, Shian-Shiang
    Li, Jian-Ri
    Chen, Chuan-Shu
    Hung, Chi-Feng
    Chen, Cheng-Che
    Wang, Shu-Chi
    Lin, Chia-Yen
    Hung, Sheng-Chun
    ONCOLOGY LETTERS, 2023, 26 (01)
  • [7] Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram
    Abdollah, Firas
    Klett, Dane E.
    Sood, Akshay
    Sammon, Jesse D.
    Pucheril, Daniel
    Dalela, Deepansh
    Diaz, Mireya
    Peabody, James O.
    Quoc-Dien Trinh
    Menon, Mani
    BJU INTERNATIONAL, 2015, 116 (05) : 703 - 712
  • [8] Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy
    Merrick, Gregory S.
    Butler, Wayne M.
    Galbreath, Robert W.
    Lief, Jonathan
    Bittner, Nathan
    Wallner, Kent E.
    Adamovich, Edward
    BJU INTERNATIONAL, 2011, 107 (02) : 226 - 232
  • [9] Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer
    Dell'Oglio, Paolo
    Karnes, Robert Jeffrey
    Joniau, Steven
    Spahn, Martin
    Gontero, Paolo
    Tosco, Lorenzo
    Fossati, Nicola
    Kneitz, Burkhard
    Chlosta, Piotr
    Graefen, Markus
    Marchioro, Giansilvio
    Bianchi, Marco
    Sanchez-Salas, Rafael
    Karakiewicz, Pierre I.
    Van Poppel, Hendrik
    Montorsi, Francesco
    Briganti, Alberto
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (05) : 234.e13 - 234.e19
  • [10] Advances in the Multimodality Management of High-risk Prostate Cancer
    Garzotto, Mark
    Hung, Arthur Y.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 22 (02) : 375 - +